Bullisch
$7.68
Szenariopreis
$13.150
+0.359 (+2.73%)Zum Schluss
InfuSystem Holdings, Inc. is a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. Its segments include Patient Services and Device Solutions. Its core service within its Patient Services segment is its Oncology Business. Patient Services supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its Device Solutions segment’s core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings, including, home care and home infusion providers and others.
InfuSystem Holdings Inc is a good buy right now, with a current price of $13.84 and a forward P/E ratio of 22.73, indicating reasonable valuation relative to future earnings. The company has shown a robust year-to-date change of +64.96% and a solid gross margin of 57.50% in Q2 2026, reflecting strong operational efficiency. The main risk is the high insider selling activity, which has increased by 1158.53% over the last quarter, suggesting potential concerns among hedge funds.
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

InfuSystem Postpones Q3 Financial Results Release

InfuSystem to Host Investor Webcast on September 24, 2026

Biotech Stocks Reach 52-Week Highs Driven by Key Catalysts

InfuSystem Reports Record Q2 2026 Revenue of $36.9 Million

InfuSystem Reports Increased Q2 Earnings and Revenue Growth
InfuSystem Holdings, Inc. is a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. Its segments include Patient Services and Device Solutions. Its core service within its Patient Services segment is its Oncology Business. Patient Services supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its Device Solutions segment’s core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings, including, home care and home infusion providers and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
InfuSystem Holdings Inc is a good buy right now, with a current price of $13.84 and a forward P/E ratio of 22.73, indicating reasonable valuation relative to future earnings. The company has shown a robust year-to-date change of +64.96% and a solid gross margin of 57.50% in Q2 2026, reflecting strong operational efficiency. The main risk is the high insider selling activity, which has increased by 1158.53% over the last quarter, suggesting potential concerns among hedge funds.
Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.